First In Class Logic Gated Allogeneic CAR Cell Therapy with RMAT Designation Phase 1 Data
- Demonstrating clinical outcomes from phase 1 trials
- Exploring predictive biomarkers to optimize response, safety and trial design in allogeneic therapies
- Showcasing how clinical data enabled regulatory progress and informed pivotal study strategies